Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status:
Completed
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to
evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's
optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric
subjects with TS.